Promising Vaccine Shows Potential in preventing Aggressive Triple-Negative Breast Cancer
Table of Contents
Cleveland, OH – Researchers at Cleveland Clinic have presented encouraging Phase I data from a groundbreaking study evaluating a novel vaccine designed to prevent triple-negative breast cancer (TNBC), a particularly aggressive and often fatal form of the disease. the findings, unveiled at the San Antonio Breast Cancer Symposium, demonstrate the vaccine’s safety, tolerability, and ability to elicit an immune response in a important majority of participants.
Triple-negative breast cancer accounts for approximately 10-15% of all breast cancers and disproportionately affects younger women and those of African American descent. Its aggressive nature and lack of common receptors – estrogen, progesterone, and HER2 – make it challenging to treat wiht conventional therapies. This new vaccine represents a potentially paradigm-shifting approach, focusing on prevention rather than treatment.
Vaccine Demonstrates Safety and Immune Response
The investigational vaccine successfully triggered an immune response in 74% of all participants enrolled in the Phase I trial. Researchers meticulously monitored participants for adverse effects, finding the vaccine to be safe and well-tolerated, with the most common side effect being mild skin inflammation at the injection site. Importantly, the study also established the maximum tolerated dose, paving the way for larger-scale trials.
“Triple-negative breast cancer remains one of the most challenging forms of the disease to treat effectively,” explains G. Thomas Budd, M.D., of Cleveland Clinic’s Cancer Institute and principal investigator of the study. “The results from this trial are promising, as they suggest the investigational vaccine is not only safe and well tolerated but also capable of inducing immune responses in over 70% of participants.”
Understanding the Phase I Clinical Trial Design
The Phase I clinical trial (NCT04674306), a collaborative effort between Cleveland Clinic and Anixa Biosciences, inc., involved 35 patients divided into three distinct cohorts, each designed to assess different aspects of the vaccine’s efficacy and safety:
* Phase Ia: This cohort included patients who had recently completed treatment for early-stage TNBC (within the past three years) and were currently tumor-free but considered at high risk of recurrence.
* Phase Ib: This group comprised patients with high-risk TNBC who were scheduled to undergo surgery. The vaccine was administered prior to surgery to assess its impact on the tumor microenvironment.
* Phase Ic: This cohort included patients with newly diagnosed, locally advanced TNBC who were initiating neoadjuvant chemotherapy (chemotherapy given before surgery). The vaccine was administered alongside chemotherapy to evaluate potential synergistic effects.
The data collected from these cohorts will be instrumental in designing the Phase II study, which will further evaluate the vaccine’s effectiveness and refine the optimal dosage and management schedule.
Looking Ahead: The Potential of Preventative Cancer Vaccines
This research represents a significant step forward in the growth of preventative cancer vaccines.By harnessing the power of the immune system, this vaccine aims to intercept TNBC before it can take hold, offering a new hope for individuals at high risk of developing this devastating disease. The ongoing research at Cleveland Clinic underscores the growing potential of immunotherapy in the fight against cancer,shifting the focus from reactive treatment to proactive prevention.
Resources:
* San Antonio Breast Cancer Symposium
* ClinicalTrials.gov – NCT04674306
*[ClevelandClinicnewsroom-First-of-its-kindPreventiveBreastCancerVaccineStudy[ClevelandClinicnewsroom-First-of-its-kindPreventiveBreastCancerVaccineStudy
Promising Vaccine Shows Potential in Preventing Aggressive Triple-Negative Breast Cancer
Cleveland, OH – Researchers at Cleveland Clinic have presented encouraging Phase I data from a novel vaccine designed to prevent triple-negative breast cancer (TNBC), a particularly aggressive and often fatal subtype of the disease. The study, unveiled at the San Antonio Breast Cancer Symposium, demonstrates the vaccine’s safety, tolerability, and ability to elicit an immune response in a significant proportion of participants.
Triple-negative breast cancer presents a substantial clinical challenge due to its aggressive nature and limited treatment options.Unlike othre breast cancer subtypes, TNBC lacks the presence of estrogen, progesterone, or HER2 receptors, rendering common hormone therapies and targeted treatments ineffective. This necessitates a reliance on chemotherapy, surgery, and radiation, highlighting the urgent need for preventative strategies.
Vaccine Demonstrates Safety and Immune Response
The investigational vaccine successfully triggered an immune response in 74% of all participants enrolled in the Phase I trial. importantly, the vaccine was found to be safe and well-tolerated, with side effects primarily limited to mild skin inflammation at the injection site. Researchers were also able to determine the maximum tolerated dose, paving the way for subsequent clinical trials.
“Triple-negative breast cancer remains one of the most challenging forms of the disease to treat effectively,” explains G. Thomas Budd, M.D., of Cleveland Clinic’s Cancer Institute and principal investigator of the study. “The results from this trial are promising, as they suggest the investigational vaccine is not only safe and well tolerated but also capable of inducing immune responses in over 70% of participants.”
Phase I Trial Design and Cohorts
The phase I clinical trial (NCT04674306),conducted in collaboration with Anixa Biosciences,Inc., at Cleveland Clinic’s Main Campus, focused on evaluating the vaccine’s safety and monitoring the resulting immune response. A total of 35 patients were divided into three cohorts, each receiving a different dosage of the vaccine.
The cohorts were comprised of:
* Cohort 1: Patients with early-stage TNBC undergoing neoadjuvant chemotherapy (chemotherapy administered before surgery).
* Cohort 2: Patients with stage I/II TNBC scheduled for surgery.
* Cohort 3: Healthy volunteers.
By including these diverse groups, researchers aimed to assess the vaccine’s impact across different stages of the disease and in individuals with varying immune profiles.
Looking Ahead: Phase II Trials and Future Implications
The findings from the Phase I study are crucial in informing the design of the upcoming Phase II trial.This next phase will focus on evaluating the vaccine’s efficacy in a larger patient population and further refining the dosage regimen.
The development of a preventative vaccine for TNBC represents a significant step forward in the fight against this devastating disease. If accomplished in later-stage trials,this vaccine could offer a vital new tool for reducing the incidence and improving the outcomes for individuals at high risk of developing triple-negative breast cancer.
Sources:
* Cleveland clinic Newsroom: https://newsroom.clevelandclinic.org/2023/12/06/cleveland-clinic-presents-promising-phase-i-data-for-triple-negative-breast-cancer-vaccine/
* San Antonio Breast Cancer Symposium: https://sabcs.org/
* ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04674306
* Medical Xpress:[https://medicalxpresscom/news[https://medicalxpresscom/news
Promising Vaccine Shows Potential in Preventing Aggressive Triple-Negative breast Cancer
Cleveland, OH – Researchers at Cleveland Clinic have presented encouraging Phase I data from a groundbreaking study evaluating a novel vaccine designed to prevent triple-negative breast cancer (TNBC), a particularly aggressive and often fatal subtype of the disease. The findings, unveiled at the San Antonio Breast Cancer Symposium, demonstrate the vaccine’s safety, tolerability, and ability to elicit a significant immune response in a substantial proportion of participants.
Triple-negative breast cancer accounts for approximately 10-15% of all breast cancers. It is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), making it unresponsive to many targeted therapies commonly used in other breast cancer subtypes. This often leaves chemotherapy as the primary treatment option, presenting significant challenges for patients.
Vaccine Demonstrates Safety and Immune Response
The Phase I clinical trial assessed the safety and immunogenicity of the investigational vaccine. Results indicated that the vaccine successfully triggered an immune response in 74% of participants. Importantly, the vaccine was well-tolerated, with the most common side effects being mild inflammation at the injection site. Researchers were also able to determine the maximum tolerated dose, paving the way for future studies.
“Triple-negative breast cancer remains one of the most challenging forms of the disease to treat effectively,” explained G. Thomas Budd, M.D.,of Cleveland Clinic’s Cancer Institute and the study’s principal investigator. “The results from this trial are promising, as they suggest the investigational vaccine is not only safe and well tolerated but also capable of inducing immune responses in over 70% of participants.”
Clinical Trial Design and Next Steps
The Phase I trial involved a carefully designed cohort study to evaluate the vaccine’s effects. Details regarding the specific patient population and trial methodology were presented at the San Antonio Breast Cancer Symposium. The data gathered from this initial phase will be instrumental in shaping the design of the upcoming Phase II study, which will further evaluate the vaccine’s efficacy and optimal dosage.
This research represents a significant step forward in the development of preventative strategies for triple-negative breast cancer, offering a potential new avenue for combating this devastating disease.The Cleveland clinic team is optimistic that continued research will ultimately lead to a viable vaccine that can protect individuals at high risk of developing TNBC.
Sources:
* Cleveland Clinic. (2024). Research on breast cancer vaccine at Cleveland Clinic. https://medicalxpress.com/news/2024-11-breast-cancer-vaccine.html?utm_source=embeddings&utm_medium=related&utm_campaign=internal
* San Antonio Breast cancer Symposium: https://sabcs.org/
* San Antonio Breast Cancer Symposium – Poster Session 4: https://sabcs.org/events/poster-session-4/
Worth a look